Aurinia Pharmaceuticals News and Activities

Aurinia Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Aurinia Pharmaceuticals is a company listed under the stock ticker AUPH (US).

View the org chart displaying its 15 main executives

Most searched biographies at Aurinia Pharmaceuticals

• Peter Greenleaf, Chief Executive Officer
• Kevin Tang, Director
• David Jayne, Director

Popular executive movements at Aurinia Pharmaceuticals

• Craig Johnson has joined the company as Director  (posted on November 8 2024).
• Robert Foster, Director, is retiring  (posted on November 8 2024).
• Kevin Tang has joined the company as Director  (posted on September 13 2024).

Click here to view some more movements at Aurinia Pharmaceuticals

Create your alert
to follow the executive moves at Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals has 1,826 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).

Popular M&A news in Pharmaceuticals

• Danone has announced the acquisition of Kate Farms  (posted on May 14 2025).
• Cyclo Therapeutics has acquired Rafael Holdings (posted on April 28 2025).
• Chimerix and Chimerix have merged  (posted on April 22 2025)..

Popular contacts in Pharmaceuticals

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets at Bristol-Myers Squibb
• Seth Harrison - Chairman and Director at Braeburn Pharmaceuticals
• Fred Davenport - Lead Director at Medpace

Learn more about the Pharmaceuticals industry

Press releases by Aurinia Pharmaceuticals

• Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
• Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
• Aurinia to Participate in Jefferies London Healthcare Conference
• Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
• Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
• Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
• Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
• Aurinia Announces Board Restructuring
• Press Releases
• Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
• View more press releases Close

Social media about Aurinia Pharmaceuticals

• Aurinia Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Aurinia Pharmaceuticals on LinkedIn, Twitter & YouTube